2. Search Result
Search Result
Results for "

glucosylceramide

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

2

Fluorescent Dye

9

Peptides

2

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144267
    Glucosylceramide synthase-IN-2

    		Glucosylceramide Synthase (GCS) Neurological Disease Metabolic Disease
    Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research .
    Glucosylceramide synthase-IN-2
  • HY-144266
    TP-060

    glucosylceramide synthase-IN-1

    		 Glucosylceramide Synthase (GCS) Neurological Disease Metabolic Disease
    Glucosylceramide synthase-IN-1 (T-036) a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research .
    TP-060
  • HY-165035
    Glucosylceramide (gaucher's spleen)

    Glucocerebrosides; Gaucher cerebroside; GluCers (gaucher's spleen)

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    Glucosylceramides are sphingolipid molecules found in both neuronal and non-neuronal mammalian tissues, as well as in low quantities across various plant species. Elevated levels of glucosylceramides provide cellular protection and prepare certain cells for proliferation; however, they have also been linked to obesity-induced insulin resistance in mice and to neuronal deficits observed in neuronopathic Gaucher disease .
    Glucosylceramide (gaucher's spleen)
  • HY-W356117
    C6 NBD Glucosylceramide

    		Fluorescent Dye Others
    C6 NBD Glucosylceramide is a glucosylceramide fluorescent derivative (Ex=466 nm, Em=535 nm). C6 NBD Glucosylceramide can be used to study the metabolism and internalization of glucosylceramide and also for the determination of glucosyl ceramide synthase activity .
    C6 NBD Glucosylceramide
  • HY-144270
    Glucosylceramide synthase-IN-3

    		Glucosylceramide Synthase (GCS) Neurological Disease Metabolic Disease
    Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research .
    Glucosylceramide synthase-IN-3
  • HY-W717504
    Glucosylceramide, plant

    		Others
    Glucosylceramide, plant is a plant-derived glycolipid with anti-inflammatory and immunomodulatory activities. Glucosylceramide, plant plays an important role in promoting cell proliferation and repair. Glucosylceramide, plant is widely used in skin care products to enhance skin barrier function. Glucosylceramide, plant has also been studied for improving nervous system health, showing potential neuroprotective effects.
    Glucosylceramide, plant
  • HY-163131
    Glucosylceramide synthase-IN-4

    		Glucosylceramide Synthase (GCS) Neurological Disease
    Glucosylceramide synthase-IN-4 (compound 12) is a potent glucosylceramide synthase (GCS) inhibitor, with an IC50 of 6.8 nM. Glucosylceramide synthase-IN-4 shows excellent PK properties and stability in human hepatocytes. Glucosylceramide synthase-IN-4 has good CNS penetration and acceptable PXR selectivity .
    Glucosylceramide synthase-IN-4
  • HY-158803
    C6 Biotin glucosylceramide (d18:1/6:0)

    C6 glucosylceramide-biotin; N-Hexanoyl-biotin-glucosylceramide

    		 Biochemical Assay Reagents Metabolic Disease
    C6 Biotin glucosylceramide (d18:1/6:0) (C6 Glucosylceramide-biotin; N-Hexanoyl-biotin-glucosylceramide) is an ester product.
    C6 Biotin glucosylceramide (d18:1/6:0)
  • HY-166250
    N-Hexanoyl-glucosylceramide

    		Biochemical Assay Reagents Metabolic Disease
    N-Hexanoyl-glucosylceramide is an ester product.
    N-Hexanoyl-glucosylceramide
  • HY-164236S
    C22 Glucosylceramide (d18:1/22:0)-d4

    		Isotope-Labeled Compounds Others Metabolic Disease
    C22 Glucosylceramide (d18:1/22:0)-d4 is deuterium labeled C22 Glucosylceramide (d18:1/22:0). C22 Glucosylceramide (d18:1/22:0) is an ester product .
    C22 Glucosylceramide (d18:1/22:0)-d4
  • HY-164236
    C22 Glucosylceramide (d18:1/22:0)

    		Biochemical Assay Reagents Metabolic Disease
    C22 Glucosylceramide (d18:1/22:0) is an ester product.
    C22 Glucosylceramide (d18:1/22:0)
  • HY-106392
    Lucerastat

    NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study .
    Lucerastat
  • HY-116535C
    D-threo-PPMP

    		Glucosylceramide Synthase (GCS) Neurological Disease
    D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP can block karyokinesis and reduce cyst production .
    D-threo-PPMP
  • HY-116535
    D-threo-PPMP hydrochloride

    		Glucosylceramide Synthase (GCS) Neurological Disease
    D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP hydrochloride can block karyokinesis and reduce cyst production .
    D-threo-PPMP hydrochloride
  • HY-N7745
    Glucosylsphingosine
    1 Publications Verification

    Glucopsychosine; Lyso-Gb1

    		 Drug Metabolite Glycosidase Neurological Disease Metabolic Disease Cancer
    Glucosylsphingosine (lyso-Gb1) is a deacylated form of glucosylceramide with neurotoxicity and is also a noncompetitively inhibitor of glucocerebrosidase with a Ki value of 30 μM. Glucosylsphingosine is promising for research of Krabbe and Gaucher disease .
    Glucosylsphingosine
  • HY-129411
    Sinbaglustat

    ACT-519276; OGT2378

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions .
    Sinbaglustat
  • HY-12744A
    Genz-123346

    		Glucosylceramide Synthase (GCS) Metabolic Disease
    Genz-123346 is a potent, orally available glucosylceramide synthase inhibitor. Genz-123346 blocks the conversion of ceramide to glucosylceramide (GL1) and inhibits GM1 with an IC50 value of 14 nM .
    Genz-123346
  • HY-116392F
    D-threo-PDMP hydrochloride

    		Others Cancer
    D-threo-PDMP hydrochloride is a glucosylceramide (GlcCer) synthase inhibitor that inhibits glucosylceramide (GlcCer) and lactosylceramide (LacCer) levels in B16 melanoma cells. D-threo-PDMP hydrochloride lacks reactivity to the other two surface antigens anti-melanoma monoclonal antibodies M562 and M622 and the major histocompatibility antigen anti-H-2KbDb monoclonal antibody, so it is specific for B16 melanoma sex .
    D-threo-PDMP hydrochloride
  • HY-110363
    Miglustat-d9 hydrochloride

    N-Butyldeoxynojirimycin-d9 hydrochloride; NB-DNJ-d9 hydrochloride; OGT 918-d9 hydrochloride

    		 Isotope-Labeled Compounds Glucosylceramide Synthase (GCS) Neurological Disease
    Miglustat-d9 (hydrochloride) is the deuterium labeled Miglustat (hydrochloride). Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1)[1][2].
    Miglustat-d9 hydrochloride
  • HY-17020S
    Miglustat-d9

    N-Butyldeoxynojirimycin-d9; NB-DNJ-d9; OGT 918-d9

    		 Isotope-Labeled Compounds Glucosylceramide Synthase (GCS) Neurological Disease
    Miglustat-d9 is the deuterium labeled Miglustat. Miglustat (N-Butyldeoxynojirimycin) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1) .
    Miglustat-d9
  • HY-116392D
    PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Apoptosis Cancer
    PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research .
    PDMP hydrochloride
  • HY-116392B
    DL-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    DL-threo-PDMP hydrochloride is the hydrochloride form of DL-threo-PDMP that is a competitive glucosylceramide synthase (GCS) inhibitor. DL-threo-PDMP resensitizes refractory testicular germ cell tumors and epithelial ovarian cancer orthoxenografts to cisplatin in mice .
    DL-threo-PDMP hydrochloride
  • HY-116392A
    (−)-L-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    (−)-L-threo-PDMP hydrochloride is the hydrochloride form of (−)-L-threo-PDMP. L-threo-PDMP is a glucosylceramide synthase (GCS) inhibitor. L-threo-PDMP stimulates the proliferation of cultured aortic smooth muscle cells, and that increases the level of LacCer in B16 melanoma cells .
    (−)-L-threo-PDMP hydrochloride
  • HY-16743C
    Ibiglustat hydrochloride

    Venglustat hydrochloride; SAR402671 hydrochloride; GZ402671 hydrochloride

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat hydrochloride
  • HY-16743
    Ibiglustat
    3 Publications Verification

    Venglustat; SAR402671; GZ402671

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat
  • HY-16743B
    Ibiglustat succinate
    3 Publications Verification

    Venglustat succinate; SAR402671 succinate; GZ402671 succinate

    		 Glucosylceramide Synthase (GCS) Neurological Disease
    Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat succinate
  • HY-16743A
    Ibiglustat (L-Malic acid)
    3 Publications Verification

    Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)

    		 Glucosylceramide Synthase (GCS) Metabolic Disease
    Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
    Ibiglustat (L-Malic acid)
  • HY-P4154
    Bevonescein

    ALM-488

    		 Fluorescent Dye Neurological Disease Cancer
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-P1103A
    CTCE-9908 TFA

    		CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    		 CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P2231A
    Cotadutide acetate
    1 Publications Verification

    MEDI0382 acetate

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-N10526
    Isoglobotriaose

    Gala-3Galb-4Glc

    		 Others Others
    Isoglobotriaose (Gala-3Galb-4Glc) is a glycosphingolipid found in mammalian tissues. Isoglobotriaose is an analogue of Globotriaose, the ganglioside derivatives of them locate in difference position of small intestine, isoglobotriaosylceramide is restricted to the nonepithelial residue, while globotriaosylceramide is in both compartments .
    Isoglobotriaose
  • HY-P2231
    Cotadutide
    1 Publications Verification

    MEDI0382

    		 GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-P4757
    N1-Glutathionyl-spermidine disulfide

    		Parasite Others
    N1-Glutathionyl-spermidine disulfide is a substrate of trypanothione reductase .
    N1-Glutathionyl-spermidine disulfide
  • HY-W356116
    C6 NBD Ceramide

    Nbd-ceramide

    		 Fluorescent Dye Others
    C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism .
    C6 NBD Ceramide
  • HY-P1321
    GR231118

    1229U91; GW1229

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A
    GR231118 TFA

    1229U91 TFA; GW1229 TFA

    		 Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: